Loading...

Ultra-LEAF™ Purified anti-mouse CD3ε Antibody

Pricing & Availability
Clone
145-2C11 (See other available formats)
Regulatory Status
RUO
Other Names
CD3ε, T3, CD3
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
145-2C11_LEAF_021606
C57BL/6 mouse splenocytes were stained with LEAF™ purified CD3e (clone 145-2C11) (filled histogram) or Armenian hamster IgG isotype control (open histogram), followed by anti-Armenian hamster IgG FITC.
  • 145-2C11_LEAF_021606
    C57BL/6 mouse splenocytes were stained with LEAF™ purified CD3e (clone 145-2C11) (filled histogram) or Armenian hamster IgG isotype control (open histogram), followed by anti-Armenian hamster IgG FITC.
Compare all formats
Cat # Size Price Save
100339 100 µg ¥10,460
100340 1 mg ¥27,230
100359 5 mg ¥96,780
100360 25 mg ¥233,730
100371 50 mg ¥390,770
100372 100 mg ¥561,580
Description

CD3ε is a 20 kD transmembrane protein, also known as CD3 or T3. It is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3ε forms a TCR complex by associating with the CD3δ, γ and ζ chains, as well as the TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
H-2Kb-specific mouse cytotoxic T lymphocyte clone BM10-37
Formulation
0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
Endotoxin Level
Less than 0.01 EU/µg of the protein (< 0.001 ng/µg of the protein) as determined by the LAL test.
Preparation
The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Concentration
The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Application

FC - Quality tested
IHC-F, IP, Activ, Block, WB, ICC - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume or 100 µl of whole blood.  It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Clone 145-2C11 is useful for in vitro blocking of target-specific CTL-mediated cell lysis1, as well as T cell activation assays, inducing proliferation and cytokine production1,2,7,12,16. It also induces apoptosis in immature thymocytes32,  and in vivo T cell depletion8-10. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1, immunohistochemical staining14,15 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, Western blotting4, complement-mediated cytotoxicity6, in vitro and in vivo stimulation of T cells1,2,7,12,16, immunofluorescent staining5, and in vivo T cell depletion8-10. The 145-2C11 antibody has been reported to block the binding of 17A2 antibody to CD3 epsilon-specific T cells11. Clone 145-2C11 is not recommended for formalin-fixed paraffin embedded sections. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100314). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100340) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Additional Product Notes

Get a 50% discount on this product when purchased in our Activation Bundles. Restrictions apply. Learn more…

View more applications data for this product in our Scientific Poster Library.

Application References

(PubMed link indicates BioLegend citation)
  1. Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block)
  2. Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ)
  3. Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1.
  4. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB)
  5. Payer E, et al. 1991. J. Immunol. 146:2536. (IF)
  6. Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD)
  7. Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ)
  8. Henrickson M, et al. 1995. Transplantation 60:828. (Deplete)
  9. Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete)
  10. Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete)
  11. Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block)
  12. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ)
  13. Ko SY, et al. 2005. J. Immunol. 175:3309.
  14. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F)
  15. Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F)
  16. Wang W, et al. 2007. J. Immunol. 178:4885. (Activ)
  17. Xiao S, et al. 2007. J. Exp. Med. 204:1691.
  18. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed.
  19. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed
  20. Guo Y, et al. 2008. Blood 112:480. PubMed
  21. Kenna TJ, et al. 2008. Blood 111:2091.
  22. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed
  23. Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed
  24. Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed
  25. de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed
  26. Schulteis RD, et al. 2008. Blood 295:G273. PubMed
  27. Qi Q, et al. 2009. Blood 114:564. PubMed
  28. Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed
  29. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  30. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
  31. Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed
  32. Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)
Product Citations
  1. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  2. Jairaman A, et al. 2021. Bio Protoc. 11:e4170. PubMed
  3. Duong–Ly KC, et al. 2018. J Cell Sci. 131:17. PubMed
  4. Denk D, et al. 2022. Immunity. 55:2059. PubMed
  5. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  6. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  7. Qi Z, et al. 2022. Nat Commun. 13:182. PubMed
  8. Wang W, et al. 2020. Cell Rep. 107936:32. PubMed
  9. Gupta SS, et al. 2019. Cell Rep. 29:1862. PubMed
  10. Donado CA, et al. 2020. Cell Reports. 31(1):107466. PubMed
  11. Zhao X, et al. 2021. Int J Oral Sci. 13:31. PubMed
  12. Byun JK, et al. 2020. Molecular Cell. 80(4):592-606.e8. PubMed
  13. Krone A, et al. 2022. Sci Rep. 218:. PubMed
  14. Menzel L, et al. 2021. Cell Rep. 37:109878. PubMed
  15. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  16. Potluri HK, et al. 2022. J Immunother Cancer. 10:. PubMed
  17. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  18. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  19. Dong L, et al. 2017. Sci Rep. 10.1038/srep36598. PubMed
  20. Montes de Oca M, et al. 2020. PLoS Pathog. 16:e1008994. PubMed
  21. Hoover DB, et al. 2020. Int Immunopharmacol. 106359:81. PubMed
  22. Sekiya T et al. 2018. Cell reports. 24(6):1627-1638 . PubMed
  23. Huang Y, et al. 2020. FASEB J. 34:1768. PubMed
  24. Pfenninger P, et al. 2022. Front Immunol. 13:777113. PubMed
  25. Stump CT, et al. 2021. Open Biol. 11:210245. PubMed
  26. He Y, et al. 2021. Cell Metabolism. 33(5):988-1000.e7. PubMed
  27. Codina A, et al. 2019. Cell Syst. 8:136. PubMed
  28. Du Y, et al. 2022. Nat Commun. 13:231. PubMed
  29. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  30. Gudgeon N, et al. 2022. Cell Rep. 40:111193. PubMed
  31. Glassman CR, et al. 2021. eLife. 10:00. PubMed
  32. Gandhi VD, et al. 2022. J Clin Invest. 132:. PubMed
  33. Herrera FG, et al. 2021. Cancer Discov. Online ahead of print. PubMed
  34. Saragovi A, et al. 2020. Elife. 9:00. PubMed
  35. Gurusamy M, et al. 2021. Nat Commun. 12:6798. PubMed
  36. Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed
  37. Han K, et al. 2021. Nat Metab. 3:318. PubMed
  38. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  39. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  40. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  41. Zhai X, et al. 2021. Sci Adv. 7:eabk0490. PubMed
  42. Zhang R, et al. 2022. Front Pharmacol. 13:870848. PubMed
  43. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  44. Takahashi F, et al. 2022. iScience. 25:104278. PubMed
  45. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  46. Woo MS, et al. 2021. J Exp Med. :218. PubMed
  47. Minns D, et al. 2021. Nat Commun. 12:1285. PubMed
  48. Wang D, et al. 2022. EMBO Rep. 23:e53691. PubMed
  49. Yang X, et al. 2021. Bioact Mater. 3150:6. PubMed
  50. Xu Y, et al. 2021. iScience. 24:103445. PubMed
  51. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  52. Sobecki M, et al. 2022. Cell Stem Cell. 29:1459. PubMed
  53. Jain A, et al. 2020. Nat Immunol. 0.920138889. PubMed
  54. Konishi Y, et al. 2018. iScience. 10:98. PubMed
  55. Luo ZW, et al. 2021. Int J Nanomedicine. 16:2949. PubMed
  56. Zhang Z, et al. 2021. Front Immunol. 12:699478. PubMed
  57. Pandit M, et al. 2022. Exp Mol Med. 54:1214. PubMed
  58. Guo Z, et al. 2022. Neurobiol Pain. 12:100096. PubMed
  59. Okubo A, et al. 2021. Int J Mol Sci. 23:. PubMed
  60. Liu Y, et al. 2021. Nat Commun. 12:6831. PubMed
  61. Fujiwara Y, et al. 2021. Nat Commun. 12:5857. PubMed
  62. Wang F, et al. 2021. Nat Commun. 12:1378. PubMed
  63. Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
RRID
AB_11150783 (BioLegend Cat. No. 100339)
AB_11149115 (BioLegend Cat. No. 100340)
AB_2616673 (BioLegend Cat. No. 100359)
AB_2616674 (BioLegend Cat. No. 100360)
AB_2800555 (BioLegend Cat. No. 100371)
AB_2800556 (BioLegend Cat. No. 100372)

Antigen Details

Structure
Ig superfamily, forms CD3/TCR complex with CD3δ, γ and ζ subunits and TCR (α/β and γ/δ), 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
TCR signal transduction, T cell activation, antigen recognition
Ligand/Receptor
Peptide antigen/MHC-complex
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules, TCRs
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12501 View all products for this Gene ID
UniProt
View information about CD3epsilon on UniProt.org

Related FAQs

Do you guarantee that your antibodies are totally pathogen free?

BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.

Does BioLegend test each Ultra-LEAF™ antibody by functional assay?

No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.

Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?

No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.

Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?

We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.

Go To Top Version: 4    Revision Date: 10/04/2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account